Le Lézard
Classified in: Health, Science and technology
Subjects: VET, MAT

/R E P E A T -- Beleave Provides Guidance on Veterans Affairs Canada Coverage/


TORONTO, May 16, 2018 /CNW/ - Beleave Inc. (CSE:  BE; OTCQX:  BLEVF) ("Beleave" or the "Company") due to an influx of inquiries from patients would like to provide guidance on the previously released Veterans Affairs Canada's Medical Cannabis Program administered by Medavie Blue Cross. 

Beleave Inc. (CNW Group/Beleave Inc.)

The program is available to patients though Veterans Affairs Canada only. For prospective patients, please refer to ACMPR guidelines for more information.

For additional patient information please contact Beleave's Director of Customer Service Anne Whelan either via email at [email protected] or by phone at 905-517-7306

Alternatively, to stay informed please join the company mailing list at www.beleave.com.

About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.

SOURCE Beleave Inc.


These press releases may also interest you

at 07:16
Creality, a global leader in the 3D printing industry, successfully concluded its presence at RAPID+TCT 2024, held from June 25 to 27 in Los Angeles, California. Renowned for showcasing cutting-edge 3D technologies, this event featured groundbreaking...

at 07:10
CyberArk , the identity security company, today announced the release of its latest Environmental, Social and Governance (ESG) report. CyberArk's approach to ESG is grounded in its commitment to its people, core values, communities and environmental...

at 07:05
Xevant, the leading provider of data analytics for healthcare solutions, and Ivím Health, the industry-leading provider of GLP-1 weight loss programs, today announced a strategic partnership between the two companies introducing the first...

at 07:05
Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic for AKEEGA® (niraparib and abiraterone acetate) from Janssen...

at 07:05
Novocure announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's...

at 07:05
AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients...



News published on and distributed by: